Krystexxa is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Savient Pharmaceuticals, Inc.. The primary component is Pegloticase.
Product ID | 54396-801_8ec18670-b429-432f-b7c5-7a43fd397c47 |
NDC | 54396-801 |
Product Type | Human Prescription Drug |
Proprietary Name | Krystexxa |
Generic Name | Pegloticase |
Dosage Form | Injection, Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2010-09-14 |
Marketing Category | BLA / BLA |
Application Number | BLA125293 |
Labeler Name | Savient Pharmaceuticals, Inc. |
Substance Name | PEGLOTICASE |
Active Ingredient Strength | 8 mg/mL |
Pharm Classes | Urate Oxidase [CS],Uric Acid-specific Enzyme [EPC] |
NDC Exclude Flag | E |
Listing Certified Through | 2017-12-31 |
Marketing Start Date | 2010-09-14 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA125293 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2010-09-14 |
Inactivation Date | 2019-11-27 |
Ingredient | Strength |
---|---|
PEGLOTICASE | 8 mg/mL |
SPL SET ID: | 5f4574d1-401f-4647-83e5-28c0f4a122a7 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
54396-801 | Krystexxa | pegloticase |
60809-801 | Krystexxa | pegloticase |
75987-080 | Krystexxa | pegloticase |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
KRYSTEXXA 77552516 3920201 Live/Registered |
HORIZON PHARMA RHEUMATOLOGY LLC 2008-08-21 |